Agenus Inc. Advances Immunotherapy Strategy for Metastatic Colorectal Cancer Patients

Agenus Inc. (AGEN) is focused on extending the reach of immunotherapy to patients with metastatic colorectal cancer and other solid tumors. The company is advancing its strategy across three fronts: clinical development, patient access, and operational readiness. Recent published data from the American Cancer Society showed that colorectal cancer is the leading cause of cancer-related death in people under 50 in the US, with mortality in younger adults continuing to worsen. Agenus aims to close the gap in immunotherapy benefits for MSS tumors, which account for 95% of metastatic colorectal cancer cases.